STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2018

Sep 5, 2018

==> picture [129 x 53] intentionally omitted <==

September 5, 2018

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited Exchange Plaza , Bandra-Kurla Complex Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Press Release

Please find attached press release issued by the Company titled:

“Strides receives USFDA approval for Potassium Chloride Extended Release Tablets Second approval from the Extended Release portfolio”

Thanks and Regards

For Strides Pharma Science Limited

Sd/Manjula Ramamurthy Company Secretary

Strides Pharma Science Limited

(Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 info@strides.com; www.strides.com

Press Release September 5, 2018

==> picture [98 x 41] intentionally omitted <==

Strides receives USFDA approval for Potassium Chloride Extended Release Tablets Second approval from the Extended Release portfolio

Product approval from flagship facility at Bangalore To be launched immediately by Strides Pharma Inc. in the US markets

Bangalore, September 5, 2018 Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Potassium Chloride Extended Release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food & Drug Administration (US FDA). This is the second Extended Release product approval for Strides and the company has a strong pipeline of products leveraging its capability in the Extended Release delivery technology. Potassium Chloride Extended-Release tablets is a generic version of Klor-Con Extended Release Tablets of Upsher-Smith and Strides is the first Indian generic company to receive this approval.

According to IQVIA MAT data, the US market for Potassium Chloride Extended Release Tablets is approximately US$ 60 Mn. The product will be manufactured at the company’s facility at Bangalore and marketed by Strides Pharma Inc. in the US Market.

The company has 78 cumulative ANDA filings with USFDA of which 52 ANDAs have been approved as of date and 26 are pending approval.

About Potassium Chloride Extended Release Tablets

For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis.

Extended release tablet is formulated in such a way that the drug is released slowly over time. This has the advantage of taking pills less often and fewer side effects, as the levels of the drug in the body are more consistent.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is global pharmaceutical Company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. The Company has a global manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 facilities for Regulated Markets and 2 facilities for the Emerging Markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

	StridesBadree Komandur,Executive Director - Finance+91 80 6784 0747Investor Relations:Kannan. N: +91 98450 54745Vikesh Kumar: +91 80 6784 0827Sandeep Baid : +91 80 6784 0791Strides Pharma Science Limited(Formerly Strides Shasun Limited)CIN : L24230MH1990PLC057062Regd. Office: 201, ‘Devavrata’, Sector - 17,Vashi, Navi Mumbai - 400 703Corp. Office: Strides House,Bannerghatta Road, Bangalore - 560076Email: investors@strides.com		PR ConsultancyFortuna PRK Srinivas Reddy: +91 90005 27213srinivas@fortunapr.comK Priya: +91 95354 25418priya@fortunapr.com